Vitamin B₁₂ as a carrier for targeted platinum delivery: in vitro cytotoxicity and mechanistic studies.
It is attractive to use vitamin B₁₂ as a carrier for targeted delivery of cytotoxic agents such as platinum complexes owing to the high demand for vitamin B₁₂ by fast proliferating cells. The basic {B₁₂-CN-Pt(II)} conjugates are recognized by intracellular enzymes and converted to coenzyme B₁₂ in an enzymatic adenosylation assay. The reductive adenosylation of {B₁₂-CN-Pt(II)} conjugates leads to the release of the Pt(II) complexes; thus, {B₁₂-CN-Pt(II)} conjugates can be considered as prodrugs. It is important not only to elucidate the activity of the cisplatin-B₁₂ conjugates, but also to understand the mode of action on a molecular level. Chemical reduction of {B₁₂-CN-Pt(II)} conjugates with cobaltocene yielded cob(II)alamin and induced release of the corresponding Pt(II) species. Kurnakov tests and coordination of 2'-deoxyguanosine or GMP to the released Pt(II) complexes allowed isolation and characterization of Pt(II) complexes as released during enzymatic adenosylation. The biological activity of these Pt(II) complexes was evaluated. Since the cleaved Pt(II) complexes show cytotoxicity, the {B₁₂-CN-Pt(II)} conjugates can be used for specific targeting of cancer cells and therapeutic drug delivery. Preliminary in vitro cytotoxicity studies indicated lower activity (IC(50) between 8 and 88 μM) than found for pure cisplatin. Since active transport and receptor-mediated uptake limits the intracellular {B₁₂-CN-Pt(II)} concentration, comparison with pure cisplatin is of limited use. We could show that the Pt(II) complexes cleaved from B₁₂ exerted a cytotoxicity comparable to that of cisplatin itself. Cytotoxicity studies in vitamin B₁₂ free media showed a dependence on the addition of transcobalamin II for B₁₂-Pt(II) conjugates.
Ruiz-Sánchez
Pilar
P
Institute of Inorganic Chemistry, University of Zurich, Winterthurerstrasse 190, Zurich, Switzerland.
König
Christiane
C
Ferrari
Stefano
S
Alberto
Roger
R
D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D003035:Cobalt / Q000737:chemistry; D004305:Dose-Response Relationship, Drug; D004337:Drug Carriers / Q000737:chemistry* / Q000633:toxicity; D016503:Drug Delivery Systems; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D008968:Molecular Conformation; D009944:Organoplatinum Compounds / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D010984:Platinum / Q000737:chemistry* / Q000494:pharmacology; D013237:Stereoisomerism; D013329:Structure-Activity Relationship; D014805:Vitamin B 12 / Q000737:chemistry* / Q000633:toxicity
D000970:Antineoplastic Agents; D004337:Drug Carriers; D009944:Organoplatinum Compounds; D003035:Cobalt; D010984:Platinum; D014805:Vitamin B 12
J Biol Chem. 2002 Sep 6;277(36):33127-31
12080060
Adv Drug Deliv Rev. 2003 Feb 24;55(3):329-47
12628320
J Pharm Pharm Sci. 2003 Jan-Apr;6(1):33-66
12753729
Acc Chem Res. 2008 Jan;41(1):2-3
18193819
J Nucl Med. 1997 May;38(5):717-23
9170435
Bioconjug Chem. 1996 Mar-Apr;7(2):217-32
8983344
Mayo Clin Proc. 2000 Jun;75(6):568-80
10852417
Bioconjug Chem. 1997 Jul-Aug;8(4):498-502
9258447
Nat Rev Cancer. 2005 Mar;5(3):161-71
15738981
J Mass Spectrom. 1996 Jul;31(7):802-9
8799307
Blood. 1997 Jan 1;89(1):235-42
8978297
Cancer Res. 2008 Apr 15;68(8):2904-11
18413759
Blood. 2009 Jan 1;113(1):186-92
18779389
J Control Release. 2007 Feb 26;117(3):421-9
17239471
J Med Chem. 2005 Feb 10;48(3):857-66
15689170
Nucl Med Biol. 2007 Oct;34(7):733-5
17921025
FEBS J. 2006 Oct;273(20):4742-53
16984395
J Org Chem. 2004 Dec 24;69(26):8987-96
15609930
J Biol Chem. 2001 Aug 24;276(34):32101-8
11408479
Chemistry. 2000 Jun 2;6(11):2002-10
10894399
Inorg Chem. 2000 Apr 17;39(8):1710-5
12526558
Cancer Res. 1991 Apr 1;51(7):1866-75
2004370
Chemistry. 2005 Jul 4;11(14):4089-95
15861475
Angew Chem Int Ed Engl. 2004 Sep 27;43(38):5025-9
15384109
Cancer. 2005 Dec 15;104(12):2658-70
16315241
J Inorg Biochem. 1979 Feb;10(1):53-65
448353
Chem Rev. 1999 Sep 8;99(9):2467-98
11749487
Inorg Chem. 2008 Sep 1;47(17):7673-80
18671390
Org Lett. 2001 Mar 22;3(6):799-801
11263885
Proc Natl Acad Sci U S A. 2008 Jul 1;105(26):8902-7
18579768
FASEB J. 2005 Mar;19(3):311-30
15746175
Target Oncol. 2009 Sep;4(3):151-68
19768637
Bioconjug Chem. 1996 Jul-Aug;7(4):461-74
8853460
J Med Chem. 2001 Dec 6;44(25):4492-6
11728195
Chem Soc Rev. 2007 Apr;36(4):665-86
17387413
Int J Pharm. 1999 Mar 15;179(2):247-55
10053217
J Biol Inorg Chem. 2008 Mar;13(3):335-47
18060564
J Am Chem Soc. 2005 Sep 21;127(37):12768-9
16159248
Mayo Clin Proc. 1999 Jul;74(7):687-91
10405698
J Control Release. 2007 Sep 26;122(2):141-50
17707540